本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Showcasing at ASCRS 2025: More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons. ZEISS MEL 90 broadens refractive treatment portfolio: U.S. availability of both the ZEISS MEL 90 and ZEISS VISUMAX 800 extends the company's LVC market leadership with treatments for myopia, hyperopia, and mixed astigmatism. Enhanced cataract portfolio with DORC and FCI: Showcasing cataract solutions from DORC and FCI for the first time in the ZEISS booth #1501. JENA, Germany and DUBLIN, Calif., April 17, 2025 /PRNewswire/ -- ZEISS Medical Technology will celebrate the rapid adoption of digital cataract solutions and showcase newly available refractive treatment technology at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25 – 27 in Los Angeles, CA. ZEISS marks a major milestone in the U.S. with more than 2 million digitally planned cases using the ZEISS VERACITY Surgery Planner,1 one of the leading digital planning solutions for cataract surgery, which serves as a testament to the growing number of surgeons discovering the benefits of digital workflows in the delivery of patient care and treatments. ZEISS VERACITY Surgery Planner "The digital era continues to grow at a rapid pace. Ophthalmologists are increasingly realizing the significant benefits of using digital workflows as the backbone of their medical practices," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "ZEISS has much to celebrate at ASCRS this year, including our continued U.S. leadership in digital innovation and ongoing commitment to improving patient care across both the cataract and refractive markets." Additionally, the ZEISS Refractive Workflow will showcase for the first time both the VISUMAX® 800 with SMILE® pro from ZEISS and the MEL® 90 from ZEISS, helping to further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes. Lastly, for the first time, DORC and FCI, both ZEISS companies, are set to present their portfolio of cataract surgical solutions in the ZEISS booth, showcasing the extended benefits of ZEISS's surgical portfolio. More than 2 million cases planned using ZEISS VERACITY Surgery Planner reflects growing digital adoption by U.S. cataract surgeons ZEISS VERACITY Surgery Planner is one of the top digital planning solutions for cataract surgery in the U.S. today with thousands of users logging in to plan their surgical cases, pulling data from most modern EMRs, 19 different diagnostic devices, and optional data sources like patient questionnaires, in order to make data-driven informed decisions designed to drive better patient outcomes in clinics and ORs. At ASCRS, ZEISS will celebrate the significant milestone of its cloud-based ZEISS VERACITY Surgery Planner, with more than 2 million cases planned. A recent study showed that with the ZEISS Cataract Workflow powered by ZEISS VERACITY Surgery Planner, surgeons and staff can save up to 60% of their time per eye compared to traditional paper planning.2 Kerry Solomon, MD, from Carolina Eye Care Physicians, one of the creators of VERACITY prior to its acquisition by ZEISS in 2017, says, "Today we're up to 2 million plans, unbelievable! When we first started developing this solution, I absolutely envisioned we'd get to where we are today, and I'm thrilled with where we're at!" In addition to proven efficiency gains, new research abstracts presented at this year's ASCRS showcase excellent refractive accuracy and clinical outcomes when adopting the ZEISS Cataract Workflow: Steven C. Schallhorn, MD, ABO, will present a clear benefit of reducing postoperative astigmatism by implanting toric IOLs in patients with lower preoperative corneal astigmatism, leveraging cataract outcomes obtained from VERACITY Surgery Planner's database of 50,850 eyes with preoperative corneal astigmatism between 0.75D and 1.50D. Luke Rebenitsch, MD, ABO, will present a comparison of refractive outcomes in a large cohort of 49,057 eyes undergoing cataract surgery with toric IOL implantation where the use of the ZEISS CALLISTO eye system resulted in significant improvements in terms of post-op refractive outcomes compared to a manual marking approach. Kamran M. Riaz, MD, ABO, will present an analysis of the refractive accuracy of two biometers in a cohort of 222 eyes with prior laser vision correction and implantation of toric multifocal IOLs, highlighting the significantly better performance of total keratometry with the IOLMaster 700. Enhanced refractive treatment portfolio enables a higher standard of refractive patient care with both the ZEISS VISUMAX 800 and ZEISS MEL 90 ZEISS continues to set high standards in refractive patient care in the U.S. with the availability of both the ZEISS VISUMAX 800 and ZEISS MEL 90. For the first time, the ZEISS MEL 90 will be showcased in the U.S. at ASCRS, extending ZEISS's LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism. "The FDA approval of the ZEISS MEL 90 excimer laser is a game changer for refractive surgery in the U.S. I am particularly impressed by the system's ability to simplify treatment planning while delivering highly predictable and tissue-conserving results. This approval marks an exciting chapter for surgeons and patients alike," says Dr. John Doane, Refractive Surgeon, Discover Vision Centers, Kansas City, MO (USA). The MEL® 90 from ZEISS aims to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro from ZEISS to help further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes. The ZEISS VISUMAX 800 with ZEISS SMILE pro software enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.3 The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise. Showcasing the benefits of ZEISS's surgical portfolio to help meet the evolving clinical challenges of surgeons in the U.S. ZEISS will showcase for the first time together in the ZEISS booth key solutions from DORC and FCI. This will feature the DORC EVA NEXUS™ surgical system for cataract and phaco-vitrectomy surgeries. It will also include the DORC VisionBlue® anterior stain, a trusted choice in more than 10 million cataract surgeries since its introduction. As the only FDA-approved trypan blue stain for anterior applications, it is also authorized for staining Descemet's membrane and trabecular meshwork. Additionally, the ZEISS booth will feature the FDA-approved Eyejet® 20C from Morcher®, built on the gold standard preloaded Eyejet® system and designed to prevent toric IOLs rotation, providing maximum toric benefits. ZEISS will showcase its latest offerings and new innovations at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 25-27, 2025, in Los Angeles, CA, at booth #1501. For more information, visit www.zeiss.com/med. 1 Data on file.2 Gujral, Tarika, and John Hovanesian. "Cataract Surgical Planning Using Online Software vs Traditional Methods." Clinical Ophthalmology (Auckland, N.Z.), U.S. National Library of Medicine, 28 July 2021.3 Data on file, myopia with optical zone 6.5 mm. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: investors.meditec@zeiss.com Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: press.med@zeiss.com www.zeiss.com/newsroom Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.For further information visit: www.zeiss.com/med ZEISS MEL 90 Excimer Laser
Collaboration with Intel® for AI-powered medical screening optimizations TAIPEI, March 31, 2025 /PRNewswire/ -- Acer Medical has recently launched its AI-assisted screening software, VeriSee Diabetic Retinopathy and VeriSee Age-Related Macular Degeneration. These innovative solutions will be showcased at the Malaysian Ophthalmology Society (MSO) Annual Congress, bringing cutting-edge AI screening technology to Malaysia's ophthalmic community.  Acer Medical collaborates with Intel® to optimize AI-powered medical screening. In collaboration with Intel, Acer Medical is advancing AI-driven medical imaging by accelerating AI inferencing and optimizing resource use with OpenVINO™ technology running on Intel® Core™ Ultra processors. OpenVINO™ is an open-source software toolkit designed for optimizing and deploying deep learning models. It significantly reduces development time by streamlining code implementation, facilitates rapid scalability, and enhances the efficiency of AI solutions. This collaboration ensures that advanced medical AI solutions can be deployed across all levels of medical institutions to process color retinal images in real-time, thereby making the solution more accessible while enhancing diagnostic efficiency and accuracy. Rising Diabetes Prevalence and Aging Population in Malaysia Drive AI Ophthalmology Adoption According to data from the Malaysian Medical Device Authority (MDA), Malaysia has one of the highest diabetes prevalence rates in Southeast Asia. Diabetes affects 18.3% of adults aged 18 and above, meaning approximately one in five Malaysians is diagnosed with the disease. With an aging population, the incidence of diabetic complications, including diabetic retinopathy, is expected to rise. Additionally, Malaysia is transitioning into an aging society, with the proportion of individuals aged 65 and above projected to reach 15.3%* by 2040. Age-related macular degeneration has become a leading cause of vision impairment among the elderly, underscoring the urgent need for early detection and preventive ophthalmic care. Acer Medical collaborates with hospitals and clinics in Malaysia to evaluate AI-driven medical solutions, enhancing diagnostic accuracy and efficiency. The VeriSee AI ophthalmic screening software analyzes color fundus images within seconds, providing high-accuracy detection of diabetic retinopathy and age-related macular degeneration. AI screening technology improves medical efficiency, enabling faster diagnoses at primary care facilities and ensuring timely treatment recommendations. Intel® OpenVINO™ Enhances AI Performance and Accessibility in Clinical Settings To ensure the seamless operation of AI medical solutions in clinical settings, Acer Medical has partnered with Intel to offer a trial program featuring the VeriSee series AI solutions with OpenVINO™ technology deployed on laptops powered by Intel® Core™ Ultra processors. This collaboration is being implemented in leading hospitals such as Universiti Malaysia Sabah Hospital (HUMS) and International Medical University (IMU) Hospital. OpenVINO™ accelerates AI inference with lower latency and higher throughput while maintaining accuracy, allowing real-time image analysis for healthcare professionals, thereby improving decision-making accuracy. In this collaboration, it optimizes the VeriSee AI series workflow, including though processing and diagnostic efficiencies. Expanding AI Healthcare Solutions Across Southeast Asia Acer Medical's VeriSee AI solutions have been adopted by leading medical institutions globally and obtained regulatory certifications from Thailand, Indonesia and the Philippines. The company remains committed to improving AI-assisted medical solutions by collaborating with local healthcare institutions. In the coming years, Acer Medical aims to further deploy AI medical solutions, optimize medical resource allocation, and improve early disease detection capabilities through strategic collaborations and continuous innovation in AI healthcare technologies. *Diabetes Medication Therapy Adherence Clinic Protocol from MOH Malaysia https://pharmacy.moh.gov.my/sites/default/files/document-upload/dmtac-protocol-2022.pdf *Healthy Ageing in Malaysia by 2030: Needs, Challenges and Future Directionshttps://pmc.ncbi.nlm.nih.gov/articles/PMC11376998/
Hsinchu, Taiwan, December 5, 2024 – ACE Biotek, in collaboration with Shin Kong Wu Ho-Su Memorial Hospital, proudly at the 2024 Taiwan Healthcare Expo. Under the theme “Generative AI Driving Medical Innovation, ESG Leading the Future of Health,” the event highlighted achievements in intelligent healthcare and sustainable development. Since signing an MOU in 2023, the partnership has focused on developing and applying the Spark Surgical Anesthesia System and the EP100 Ophthalmology Recording System (EaglePark100). Interactive on-site demonstrations attracted numerous medical professionals. The opening day featured key leadership figures from Shin Kong Wu Ho-Su Memorial Hospital, including Chairman Eugene Wu, Superintendent Sheng-Mao Hou, and Vice Superintendent Tzu-Jen Hung, engaging with attendees. Dr. Nina Kao, Executive Director of Changhua Christian Hospital's Overseas Medical Mission Center, led a delegation of 30 hospital representatives from Thailand and Papua New Guinea to visit the booth, highlighting the global interest in intelligent medical technologies and showcasing the widespread acclaim for ACE Biotek's innovations. ACE Biotek presented two flagship solutions, the EP100 Ophthalmology Recording System (EaglePark100) and the Spark Surgical Anesthesia System. The EP100 focuses on data sharing and collaboration, seamlessly integrating examination rooms with clinics. It enables digitized, structured, and paperless data management, significantly enhancing medical efficiency and precision and benefiting physicians, nurses, and technicians alike. Meanwhile, the Spark Surgical Anesthesia System integrates anesthesia data throughout surgical processes, from physiological monitors to anesthesia machines, ensuring real-time data recording and seamless data flow. It can flexibly integrate with hospital HIS, surgery, and pricing systems while leveraging AI-powered medical big data to improve operational efficiency and accuracy, helping hospitals achieve smarter, standardized surgical management. Steve Hsu, President of ACE Biotek, remarked: "We are honored to collaborate with Shin Kong Wu Ho-Su Memorial Hospital, supporting their ESG sustainability goals with innovative smart healthcare solutions. This exhibition showcases ACE Biotek's leadership in advanced medical technologies and our commitment to fostering partnerships to advance the globalization of smart healthcare." Shin Kong Wu Ho-Su Memorial Hospital remains committed to ESG principles, reducing carbon emissions and setting a benchmark for sustainability within the healthcare industry. By collaborating with ACE Biotek, the hospital is advancing its digital transformation towards a comprehensive smart hospital framework. ACE Biotek will continue innovating and developing cutting-edge smart medical solutions, fostering partnerships to elevate the next generation of healthcare and contributing to the development of green, sustainable smart hospitals. About ACE Biotek Established in 2000, ACE Group has grown for more than 20 years across wireless and healthcare industries. Originally, ACE Group formed ACE Solution as its first foray to focus on wireless communication, networking hardware, and customized system integration projects. Driven by President Steve’s vision to improve healthcare quality, he built the ACE Biotek building from the ground up and officially founded ACE Biotek in 2018. ACE Biotek integrates the past 20 years of industrial experience and knowledge to solve unmet clinical needs. In order to achieve the early diagnosis of diseases, we have developed smart medical solutions regarding imaging algorithms, cloud computing, artificial intelligence, and terahertz technology so far. Long term, ACE Biotek will expand globally to serve as a platform to cultivate talents and support tech companies to transform into Medtech. Contact ACE Biotek Advanced ACE Biotek Co., Ltd.Address: No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County 302, Taiwan (Hsinchu Biomedical Science Park)Phone: +886-3-5500909E-mail: service@acebiotek.comWebsite: https://www.acebiotek.com/Facebook: https://www.facebook.com/Acebiotek/LinkedIn: https://www.linkedin.com/company/30620922/admin/
Hsinchu, Taiwan, November 7, 2024 – ACE Biotek is at the forefront of smart hospital development in Taiwan, focusing on digital integration systems for ophthalmology, anesthesia, and electronic medical records. These advanced healthcare solutions have been successfully implemented at Shin Kong Wu Ho-Su Memorial Hospital and other leading healthcare institutions across Taiwan, receiving widespread acclaim. ACE Biotek has been invited to exhibit its solutions at the 2024 Healthcare Expo Taiwan from December 5 to December 8. We warmly invite industry professionals to visit our booth and experience the technology firsthand. Don't miss this opportunity to witness the future of healthcare! The EP100 Ophthalmology Recording System (EaglePark100) can connect with ophthalmic examination equipment, allowing patient data and examination results to be directly displayed on tablet devices, eliminating the need for thermal paper printing and achieving structured data management and a paperless workflow. It supports real-time data transfer among multiple roles, including attending physicians, assistant doctors, nurses, and examination rooms, enhancing clinical efficiency. The user-friendly interface also enables physicians to hand-draw diagnostic illustrations. The Spark Surgical Anesthesia System digitally integrates data processing for pre-, intra-, and post-operative care across nursing and anesthesia departments, supporting medication management and surgical protocols. It achieves a "real-time and comprehensive collection of physiological monitor and anesthesia machine data." Leveraging medical AI and big data analysis, the system can seamlessly connect with hospital HIS, surgical, and billing systems, significantly enhancing operational efficiency and accuracy by recording real-time anesthesia events and medical interventions. Exhibition Highlights: 🏥 Spark Surgical Anesthesia System 📝 EP100 Ophthalmology Recording System (EaglePark100) 💡 DS Data Integration System Exhibition Information: 🌟Location: TaiNEX Hall 1, Booth J118 @ Shin Kong Wu Ho-Su Memorial Hospital ACE Biotek is seeking collaboration with hospitals and international system integrators (SIs). We welcome healthcare institutions and SI partners from around the world to visit and discuss potential technical and business partnerships. 👉🏻 Booth Tour spots are limited and will be arranged based on availability, so please register early: https://docs.google.com/forms/d/e/1FAIpQLSci4DL2BZeePk-xAcF-wSOk6284zsjLEA7pzCdBC3InGQqfPA/viewform Contact: Jenny Lin (Marketing Assistant Manager) jenny_lin@acebiotek.com +886-3-5500909#3407/ +886-922168765 About ACE Biotek Established in 2000, ACE Group has grown for more than 20 years across wireless and healthcare industries. Originally, ACE Group formed ACE Solution as its first foray to focus on wireless communication, networking hardware, and customized system integration projects. Driven by President Steve’s vision to improve healthcare quality, he built the ACE Biotek building from the ground up and officially founded ACE Biotek in 2018. ACE Biotek integrates the past 20 years of industrial experience and knowledge to solve unmet clinical needs. In order to achieve the early diagnosis of diseases, we have developed smart medical solutions regarding imaging algorithms, cloud computing, artificial intelligence, and terahertz technology so far. Long term, ACE Biotek will expand globally to serve as a platform to cultivate talents and support tech companies to transform into Medtech. Contact ACE Biotek Advanced ACE Biotek Co., Ltd. Address: No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County 302, Taiwan (Hsinchu Biomedical Science Park) Phone: +886-3-5500909 E-mail: service@acebiotek.com Website: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 23, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today that the Company's U.S. subsidiary, Wincal Biopharm, Inc. ("WincalBio"), will present preclinical findings on its innovative ocular drug delivery platform at the upcoming conference, Association for Research in Vision and Ophthalmology (ARVO), the world's largest ophthalmology conference which will be held from May 5th to 9th, 2024 in Seattle, WA, United States. Based in South San Francisco, California, WincalBio is an emerging biotech dedicated to developing next-generation ocular drug delivery platforms and therapeutics for vascular diseases. Its proprietary Ocular Penetration Carrier (OPC) screening platform has shown high potential in treating various ocular diseases using eyedrop formulation of antibody therapeutics, thereby replacing the need for intravitreal injections. This novel OPC platform has a mechanism in facilitating the delivery of antibody therapeutics through the vitreous humor of the eye, reaching critical structures such as the aqueous chamber, vitreous, retina, and choroid. WincalBio stands as a pioneer in biotech industry with a leading program validated in mouse CNV models for anti-VEGF antibody therapies, a significant advancement in treating age-related macular degeneration (AMD) and diabetic macular edema (DME). These breakthroughs, along with preclinical data from various animal models, will be unveiled for the first time at ARVO 2024. While anti-VEGF antibody therapies are the standard of care for AMD treatment, they are currently limited to intravitreal injections. Dr. TaeWeon Lee, Chief Scientific Officer of WincalBio, underscored the importance of presenting these groundbreaking findings at ARVO, noting, "The OPC platform, developed internally over the past few years, has never been publicly disclosed. Presenting the preclinical data for the first time at ARVO holds tremendous significance." Additionally, Dr. Venice Chiueh, Director at WincalBio and the oral presenter, expressed gratitude for the keen interest of ARVO meeting organizers. "We appreciate the opportunity provided by ARVO reviewers to present advancements in eyedrop development. We are committed to ensuring the success of clinical studies aimed at transitioning existing patients from intravitreal injections to eyedrop applications." Eyedrop applications of therapeutics offer significant advantage of being non-invasive, as well as enhancing patient convenience with minimum side effects. While effectively delivering sufficient quantities of the therapeutics to the back of the eye remains the primary challenge for topical applications, WincalBio's OPC platform aims to overcome this challenge. ARVO, founded in 1928, is the world's largest ophthalmology conference with over 10,000 members from over 75 countries. The schedule of the presentation is as follows: Presentation Number: 2159 Presentation Title: Development of eyedrops for anti-VEGF therapeutic antibodies as a substitute for IVT injection for posterior ocular disease indications Session Number: 240 Session Title: Advancements in age-related macular degeneration: Novel drugs, delivery systems, and mechanistic insights Session Date/Start Time: May 6, 2024 from 3:00 PM to 3:15 PM Room: Yakima 1 (Seattle Convention Center - Arch Building) About Wincal Biopharm, Inc. Wincal Biopharm (WincalBio) is focused on developing vascular therapeutics. Our current focus is on developing eyedrop formulations for therapeutic antibodies using proprietary Ocular Penetration Carrier (OPC) screening platform to identify a matching antibody:carrier pair that allows therapeutic antibodies reach intraocular space including aqueous chamber, vitreous, retina and choroid, which is difficult without injection. This non-invasive eyedrop delivery of therapeutic antibodies without intravitreal injections opens up broader treatment opportunities for multiple intraocular diseases including wet AMD, DME, diabetic retinopathy, uveitis, geographic atrophy, thyroid eye disease and uveal melanoma to lower the treatment burden for both patients and clinicians. It can be used as a monotherapy with already FDA approved anti-VEGF antibodies as well as combination with other novel target antibodies including cytokine targets such as ILs (IL-1, IL-4, IL-6, IL-10, IL-17, IL-18, IL-23), TNFa, TGFb, FGF, PDGF, FasL, EGFR as well as ocular cancer targets (PD-1, PD-L1, CTLA4). Currently, anti-VEGF antibody is a lead program with preclinical efficacy demonstration in mouse CNV model, and planning to do clinical studies in 2026 followed by other novel target antibody programs and combination programs. At WincalBio, our commitment to in vivo science with a needle free drug delivery underpins to improve patient's quality of life and compliance. About OPC Platform Ocular Penetration Carrier (OPC) platform is an in vivo ocular penetration screening to quickly identify a matching cargo protein to carrier formulation from our proprietary carrier library. Delivered target protein localization from cornea, anterior chamber, vitreous, retina, choroid and optic nerve can be monitored with a labeled fluorescent signal. A wide variety of large molecule therapeutic candidates including Fab, scFv, IgGs, Fc fusion proteins, recombinant proteins and growth factors can be delivered to the back of eye. Our proprietary carriers were designed to facilitate large molecules to intraocular target area. About Aflibercept-ED (WBP-101) Aflibercept-ED (WBP-101) is an aflibercept/OPC eyedrop formulation to target retinal area without using needles. Aflibercept has been clinically well proven anti-VEGF therapeutics with the delivery route of intravitreal injections. WBP-101 eyedrop application can significantly improve ease of use and avoid injection related issues including pain, bleeding, infection or inflammation and may improve patient adherence rate by lowering treatment related burdens. Patients can easily apply eyedrops at home, which can replace IVT injection procedures for ocular disease treatment. WBP-101 can be a primary monotherapy or can be used as a maintenance therapy after an initial IVT injection. Combination therapy is also possible by delivering different pathway blocking antibodies in a single formulation. Preclinical PoC in mouse CNV model demonstrated a comparable efficacy profile to the IVT injected. For additional information about Wincal Biopharm, Inc., visit https://www.wincalbio.com.
ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic medical devices and surgery. JENA, Germany and DUBLIN, Calif., April 4, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG announced today that, after securing all required regulatory approvals, it has completed the acquisition of 100% of D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. The acquisition enhances and complements ZEISS Medical Technology's broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, spanning retina and cornea disorders, cataract, glaucoma, and refractive errors. Dutch Ophthalmic Research Center (D.O.R.C.) "Together we are better. Today holds significant importance for us as we bring our teams together and turn our collective attention toward delivering breakthrough innovations and solutions for our customers. We are very excited to welcome D.O.R.C.'s team members to our ZEISS family and to begin integrating our products and practices as we work toward a brighter future together," says Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG. "Together we can offer an unmatched portfolio of advanced technologies and digital workflows. With D.O.R.C., we have an incredible opportunity to serve ophthalmologists around the world with more complete workflows and solutions than ever before," says Euan S. Thomson, Ph.D., President of Ophthalmology and Head of the Digital Business Unit for ZEISS Medical Technology. "We've set our sights high to become the top player in the world for ophthalmology by leveraging our workflow solutions, enhancing our portfolio offerings and market position in the anterior surgery segment, and by significantly expanding our presence in the posterior surgery segment." "Together we are stronger. With four decades behind our amazing business and surgeon-inspired innovation, we look forward to writing the next chapter of our success story together with ZEISS Medical Technology," says Pierre Billardon, CEO of D.O.R.C. "By joining forces, we can extend our reach, scale our efforts, and accelerate ophthalmic surgery advancements for more surgeons faster than before. I am filled with a great sense of pride and gratitude for every D.O.R.C. team member. Together, we have achieved so much to arrive at this pivotal moment in our journey. And together with ZEISS, we have so much more to accomplish in our bright future ahead to help patients see again." Combination of portfolios will create unmatched end-to-end solution within the digitally-connected ZEISS Retina Surgery Workflow As a leading player in the retina surgical devices and consumables market, D.O.R.C.'s contributions will be critical to ZEISS Medical Technology's long-term strategy and success going forward. With D.O.R.C., ZEISS is in a unique position to offer an unmatched portfolio of market-leading technologies to ophthalmologists, including an expanded, digitally-connected Retina Surgery Workflow from ZEISS. The companies' portfolios are highly complementary and the powerful combination of the EVA NEXUS® platform from D.O.R.C. with ZEISS's extensive range of visualization, diagnostic and therapeutic devices, and surgical instruments and consumables, all connected to a digital ecosystem, will enable the creation of efficient clinical workflows that will reshape the ophthalmology market for the benefit of surgeons and their patients alike. D.O.R.C. brings to the acquisition one of the market's most advanced dual-function systems - the EVA NEXUS platform. EVA NEXUS is the core of a strong portfolio, comprising a full range of accessories, instruments and liquids, offering one of the best-in-class solutions across vitreo-retinal (VR) and combined cataract procedures. The expansion that D.O.R.C.'s overall portfolio brings to ZEISS ensures that surgeons will have more options to choose the solutions that best meet their specific surgical requirements and preferences. With the completion of this acquisition, health care professionals can expect to benefit from an extensive and unique combination of digitally connected devices and workflow solutions, from clinical pre-operative needs to the surgical operating room. This supports efficient clinical workflows and helps surgeons to improve outcomes for their patients. The two companies' immediate priorities span maintaining business continuity and customer satisfaction, cultivating areas of deep expertise, and enhancing the value of their solutions and services for current and future customers. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. Contact for investors:Sebastian FrericksHead of Group Finance and Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: investors.meditec@zeiss.com Contact for the press: Frank E. Smith Head of Global Communications OphthalmologyCarl Zeiss Meditec AGPhone: +1 925 487 3036 Mail: frank.smith@zeiss.com www.zeiss.com/newsroom Company Profiles: Carl Zeiss Meditec AG Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For more information visit our website at www.zeiss.com/med. About D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. D.O.R.C. is one of the world's leading suppliers of equipment, instruments, and liquids for ophthalmic surgery. For 40 years, D.O.R.C. has grown into a successful international business, shaping its product portfolio through close collaboration with leading top surgeons. The company improves eye surgery globally and maximizes surgeon control by providing innovative quality approaches for eye disorders. Its products are exported to more than 80 countries worldwide. The company is headquartered in Zuidland, the Netherlands, and has more than 800 employees.
A12 藝術空間
ophthalmology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
